New Exploratory Alzheimer’s Drug ANAVEX 2-73: Assessment of Safety and Cognitive Performance in a Phase 2a Study in mild-to-moderate Alzheimer’s Patients. November 27, 2015
Anavex to Present at American Epilepsy Society Annual Meeting ANAVEX 2-73 Demonstrates Anti-Seizure Effects in Well Established Preclinical Seizure Models November 19, 2015
New Exploratory Alzheimer’s Drug ANAVEX 2-73 Changes in Electrophysiological Markers in Alzheimer’s Disease – First Patient Data from an ongoing Phase 2a Study in mild-to-moderate Alzheimer’s Patients. November 11, 2015
Anavex Announces Positive Primary and Secondary Endpoints were Achieved in a Phase 2a Clinical Trial of ANAVEX 2-73 in Alzheimer’s Disease November 9, 2015
Anavex to Present Interim Phase 2a Clinical Trial Data of ANAVEX 2-73 at Late-Breaking Oral Session of CTAD 2015 Conference October 7, 2015
